| First Author | Berner VK | Year | 2015 |
| Journal | Cell Immunol | Volume | 298 |
| Issue | 1-2 | Pages | 104-14 |
| PubMed ID | 26549577 | Mgi Jnum | J:234525 |
| Mgi Id | MGI:5790161 | Doi | 10.1016/j.cellimm.2015.10.007 |
| Citation | Berner VK, et al. (2015) Microparticulate beta-glucan vaccine conjugates phagocytized by dendritic cells activate both naive CD4 and CD8 T cells in vitro. Cell Immunol 298(1-2):104-14 |
| abstractText | Microparticulate beta-glucan (MG) conjugated to vaccine antigen has been shown to serve as an effective adjuvant in vivo. To further study antigen presentation by MG:vaccine conjugates, bone marrow-derived dendritic cells (BMDC) were treated with MG conjugated to ovalbumin (OVA), then interacted with splenocytes from DO11.10 transgenic mice expressing an OVA peptide-specific T cell receptor. BMDC treated with MG:OVA induced significantly higher numbers of activated (CD25+CD69+) OVA-specific CD4+ T cells than BMDC treated with OVA alone. BMDC treated with MG:OVA upregulated CD86 and CD40 expression as well as MG alone, indicating that conjugation of OVA does not alter the immunostimulatory capacity of MG. Activation of CD8+ OVA-specific OT-1 cells showed that MG:OVA is also capable of enhancing cross-presentation by BMDC to CD8+ cytotoxic T cells. These results show that MG acts as an adjuvant to enhance antigen presentation by dendritic cells to naive, antigen-specific CD4 and CD8 T cells. |
